Trump Buys SpaceX Shares After Record IPO 
Woodside Drops $5 Billion Clean Energy Plan as Profit Rises 7% 
California Seeks Paramount Divestitures in Warner Bros. Merger 
Bathla Group Hires Administrators as Australia Housing Slump Deepens 
J.P. Morgan Upgrades Diploma, Lifts Price Target to 8,250p 
SoftBank Plans Record $6.3 Billion Bond Sale to Fund OpenAI Investments 
Luxshare Shares Rise as First-Half Profit Jumps 18% 
Ampol Profit Surges as Refining Margins Hit Record Highs 
Alibaba Raises $10.2 Billion to Expand AI Infrastructure 
Amazon to Expand Drone Delivery to 500 U.S. Locations 
Nvidia Options Price in $280 Billion Earnings Swing 
Tesla Raises Cybertruck Prices by $5,000 in US 
Australia’s Big Four Banks Face Mortgage Slowdown as Valuations Draw Scrutiny 
KPMG Australia Cuts 5% of Workforce Amid Scandal 
Tokio Marine Eyes Multibillion-Dollar Suncorp Takeover 
TikTok, DOJ Reach $400 Million Children’s Privacy Settlement 
Adidas, Puma Shares Fall as Dick’s Sporting Goods Cuts Outlook 
Add as a preferred source on Google
WEST LAFAYETTE, Ind., May 02, 2018 -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced that the company will host a conference call on Wednesday, May 9th, at 8:30 a.m. EDT to discuss its first quarter financial results and provide an operational update.
Investors and the general public are invited to listen to a live webcast of the call, which can be accessed in the Investors & News section of the Company’s website at www.endocyte.com or by dialing (877) 845-0711 (U.S./Canada) or (760) 298-5081 (International).
The webcast will be recorded and available on the Company’s website for 90 days following the call.
Website Information
Endocyte routinely posts important information for investors on its website, www.endocyte.com, in the “Investors & News” section. Endocyte uses this website as a means of disclosing material information in compliance with its disclosure obligations under Regulation FD. Accordingly, investors should monitor the “Investors & News” section of Endocyte’s website, in addition to following its press releases, SEC filings, public conference calls, presentations and webcasts. The information contained on, or that may be accessed through, Endocyte’s website is not incorporated by reference into, and is not a part of, this document.
About Endocyte
Endocyte is a biopharmaceutical company and leader in developing targeted therapies for the personalized treatment of cancer. The company's drug conjugation technology targets therapeutics and companion imaging agents specifically to the site of diseased cells. Endocyte's lead program is a prostate specific membrane antigen (PSMA)-targeted radioligand therapy, 177Lu-PSMA-617, entering phase 3 for metastatic castration resistant prostate cancer (mCRPC). Endocyte is also advancing its adaptor-controlled CAR T-cell therapy into the clinic in 2018, where it will be studied in osteosarcoma. For additional information, please visit Endocyte's website at www.endocyte.com.
Investor Contact:
Stephanie Ascher, Stern Investor Relations, Inc., (212) 362-1200, [email protected]
